Web developed by Josh Bolinger website design

The Global Leader in Preclinical Ophthalmic Research


Proprietary MiDROPS™ technology is also available to formulate small lipohilic molecules for topical instillation (eyedrop).  This patented technology platform can deliver test agents to both the anterior and posterior segments of the eye.



EyeCRO provides numerous in-vivo research models to enable directed and meaningful preclinical drug discovery and development programs. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.

Once-daily MiDROPS™ are superior to other Cyclosporine drops dosed 2x/day and provide faster therapeutic benefit to patients

"Ophthalmic distribution studies indicate significantly increased drug concentration with … Read More

EyeCRO and MPI Research Partner to Develop New Preclinical Models of Ophthalmic Disease

Oklahoma City, OK; Ann Arbor, MI; and Mattawan, MI (PRWEB) May 01, 2017 EyeCRO and MPI Research, … Read More

Inhibition of Stat3 by a Small Molecule Inhibitor Slows Vision Loss in a Rat Model of Diabetic Retinopathy

"Diabetic retinopathy is a leading cause of vision loss. Previous studies have shown signaling … Read More

More News

Tuesday, January 22nd, 2019 at 3:00pm
Aurinia's Dry Eye Syndrome Drug Produces Mixed Results In Mid-Stage Trial https://t.co/iwosXclVRd
Tuesday, January 22nd, 2019 at 7:05am
Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10) Nasdaq:EDIT https://t.co/nfRdYm9g2T
Monday, January 21st, 2019 at 10:04am
Chinese scientist who gene-edited babies fired by university https://t.co/dhecQAfbfA
Thursday, January 17th, 2019 at 4:47pm
Allergan and Mohawk tribe ask SCOTUS to review controversial Restasis patent licensing deal | FiercePharma https://t.co/HXoFtdCAc5
Preclinical Ophthalmic Contract Research